TransCode Therapeutics, Inc. RNAZ

RNAZ Company Overview

TransCode Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of RNA-based therapeutics designed to treat metastatic cancers. The company operates within the oncology and genetic medicine sectors, with a primary emphasis on delivering nucleic acid therapeutics using proprietary nanoparticle delivery technologies. Its core objective is to improve the systemic delivery and intracellular uptake of RNA therapeutics targeting genes associated with cancer progression and metastasis.

The company’s primary development platform centers on its proprietary TTX nanoparticle platform, which is designed to enable the targeted delivery of RNA therapeutics while reducing degradation and improving tumor penetration. TransCode’s lead therapeutic candidate is TTX-MC138, an investigational microRNA-targeting therapy intended to inhibit microRNA-10b, which has been associated with metastatic disease progression across multiple cancer types. The company evolved from research initiatives focused on overcoming delivery limitations in RNA therapeutics and became publicly traded on the Nasdaq Capital Market under the ticker RNAZ following its initial public offering in 2021. Public disclosures in SEC filings and company investor materials consistently identify oncology-focused RNA delivery as the company’s principal strategic focus.